Takeda Pharmaceutical Co. Ltd. and Arbor Pharmaceuticals Ireland Ltd. have entered into a license, development and commercialization agreement providing Arbor with exclusive rights to market EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. Takeda will receive an upfront payment along with future milestone and royalty payments based on sales.

"This is an opportunity to capture the value that we've created in developing and launching the EDARBI family of products while positioning us to optimize our commercial resources to support our recent and anticipated launches of new products," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "We are pleased to entrust the EDARBI family in the United States to Arbor who will continue to ensure EDARBI products are available as a treatment option to patients with hypertension. Takeda maintains its global commitment to find new therapies and expand upon the cardiovascular metabolic franchise. The EDARBI family of products remains a priority for a variety of Takeda's markets globally."

"We are excited about our acquisition of U.S. rights to EDARBI and EDARBYCLOR and look forward to representing these important brands to patients and healthcare providers," said Ed Schutter, president and chief executive officer of Arbor. "As a specialty pharmaceutical company already focused in the cardiovascular area, we are well-positioned to ensure the EDARBI products are available to all appropriate patients who may need them."

IO Biotech, a clinical-stage biopharma company developing immune modulating anti-cancer therapies, has entered into a collaborative agreement with Merck focused on the clinical evaluation of IO102 with KEYTRUDA (pembrolizumab) in non-small cell lung…